Tumour vascularisation: a druggable target.
Tumour growth, spreading and metastasis require the development of a local vasculature. There have been great advances in the understanding of how this new vasculature arises, particularly in our increased knowledge of the process of angiogenesis, Although, a vast number of pro-angiogenic and anti-angiogenic mediators have been identified, one of the key signalling processes in the development of the tumour vasculature is the hypoxia-induced stimulation of vascular endothelial cell growth factors (VEGFs) production. Anti-VEGF therapy therefore not only provides a new paradigm for limiting tumour growth via targeting angiogenesis, but also provides prototypic agents to test the hypothesis that by controlling the development of the tumour vasculature we are able to limit, and potentially stop, tumour growth and spreading.
Bishop-Bailey
David
D
Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, United Kingdom. d.bishop-bailey@qmul.ac.uk
D043924:Angiogenesis Modulating Agents / Q000378:metabolism* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D009369:Neoplasms / Q000098:blood supply* / Q000378:metabolism / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D013927:Thrombosis / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects / Q000378:metabolism / Q000502:physiology
D043924:Angiogenesis Modulating Agents; D042461:Vascular Endothelial Growth Factor A